论文部分内容阅读
葛兰素史克(GSK)涉贿事情仍在继续发酵,而且绝非孤案。比利时制药商优时比(UCB)在7月19日证实,当周受到中国国家工商行政管理总局的调查。英国制药公司阿斯利康也在7月22日发言称,中国警方于19日访问了该公司位于上海的办事处,并从公司带走了一名职员进行问话。是否步葛兰素史克后尘,正待继续关注。事实上,医药行业行贿早已经是公开的秘密,此次葛兰素史克案发,
GlaxoSmithKline (GSK) bribery things continue to ferment, but not solitary. The Belgian pharmaceutical company UCB confirmed on July 19 that it was investigated by China’s State Administration for Industry and Commerce during the week. AstraZeneca, the British pharmaceutical company, also made a speech on July 22, saying the Chinese police visited the company’s Shanghai office on the 19th and took a staff member from the company to interrogate the company. Whether or step step GSK follow-up, awaiting continued attention. In fact, the bribery in the pharmaceutical industry has long been an open secret, the case of GSK,